Article Text

Download PDFPDF
Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis

Statistics from


  • Contributors AP: study design; laboratory work. AP and IK: data collection; manuscript writing. IK, AT, GTP and AP: data analyses and interpretation. All co-authors: manuscript revisions.

  • Funding This study was approved by Moorfields Eye Hospital R&D (study number CaRS_PETA_01) and the patient has given written informed consent for publication. Iris Kleerekooper thanks the ECTRIMS for their support through the Postdoctoral International Research Fellowship. S Anand Trip receives support from the National Institute for Health Research (NIHR) Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London. AP was supported by the NIHR Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.

  • Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

  • Competing interests AP is a member of the steering committee for the OCTiMS study (Novartis) and ARI network (Zeiss), no consulting fees. Performs OCT QC for the Passos study (Novartis) and received consulting fees; received speaker fees from Heidelberg Engineering. IK, SAT and GTP report no disclosures.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.